Welcome to our dedicated page for COSCIENS BIOPHARMA news (Ticker: CSCIF), a resource for investors and traders seeking the latest updates and insights on COSCIENS BIOPHARMA stock.
COSCIENS Biopharma Inc. reports developments for a life science company focused on natural, plant-based active ingredients, with additional disclosures covering pharmaceutical therapies, diagnostic products, and related corporate actions. Company news includes operating and financial results, restructuring and cost-management updates, strategic decisions affecting subsidiaries, and commercialization matters for Macrilen, an oral diagnostic test for adult growth hormone deficiency.
Recurring updates also cover public-company status matters, including the company’s voluntary Nasdaq delisting, plans involving U.S. reporting obligations, shareholder meeting materials, capital-structure proposals, and responses to market activity in its common shares.
COSCIENS Biopharma (CSCIF) closed the second tranche of its non-brokered private placement of 15% unsecured convertible debentures, bringing the aggregate principal amount issued to approximately US$10,706,250.
The Offering contemplates up to US$20 million of debentures, and COSCIENS expects to close one or more additional tranches in the coming weeks, subject to customary conditions. Under Toronto Stock Exchange rules, the conversion rights and certain related terms of the debentures require shareholder approval, which the company plans to seek at a meeting to be held within six months. Finder’s fees for the second tranche totalled US$35,000 in debentures and US$100,000 in cash, and all debentures and underlying common shares are subject to a four‑month Canadian securities law hold period.
COSCIENS Biopharma (CSCIF) completed the acquisition of Montreal-based Nualtis Corp. for a cash purchase price of US$15 million on September 10, 2026.
COSCIENS paid US$9 million at closing, with a further US$6 million due within six months, plus up to four earn-out payments equal to 10% of Nualtis’ adjusted EBITDA for 2027–2030. Nualtis contributes an FDA- and Health Canada-inspected OTF manufacturing facility, 21 foundational patents, and diversified human and animal health pipelines, including RizaFilm®, the first FDA-approved oral dissolvable film for migraine in U.S. adults and pediatric patients.
To fund the deal, COSCIENS closed a first tranche of unsecured convertible debentures of approximately US$6 million at 15% annual interest, part of a potential US$20 million issue, convertible at US$7.00 per share subject to shareholder and TSX approvals, implying possible material dilution.
COSCIENS Biopharma (TSX: CSCI, OTCQB: CSCIF) reported Q2 2026 total revenue of $3.1 million, up from $2.4 million in Q2 2025, and a sharply reduced consolidated net loss of $0.2 million versus $2.7 million a year earlier. For the first half of 2026, total revenue rose to $5.0 million from $3.8 million, while consolidated net income reached $10.6 million (vs. a $6.4 million loss), largely driven by $10.9 million of income from discontinued German operations and higher gross margins. Continuing operations posted a modest H1 2026 net loss of $0.4 million, compared with a $4.9 million loss in 2025, as operating expenses fell to $2.8 million from $5.7 million. Cash and equivalents stood at $5.3 million on June 30, 2026.
The company completed a share reorganization effective July 3, 2026, involving a 1-for-150 consolidation and 50-for-1 split, with holders of fewer than 150 pre-consolidation shares cashed out at $1.60 per share. This enabled COSCIENS to file Form 15F on July 6, 2026, suspending its U.S. Exchange Act reporting obligations and targeting annualized cost savings, while maintaining listings on the TSX and OTCQB and continuing Canadian reporting.
COSCIENS Biopharma (TSX: CSCI, OTCQB: CSCIF) completed a share capital amendment effective July 3, 2026. The company implemented a 1-for-150 consolidation of common shares followed by a 50-for-1 split, resulting in each continuing shareholder’s pre-Consolidation interest being reduced by a factor of three.
Shareholders holding fewer than 150 common shares as of July 2, 2026 became entitled to a US$1.60 cash payment instead of participating in the split. COSCIENS expects TSX trading on a post-amendment basis within two business days and plans to file Form 15 on July 6, 2026 to suspend its U.S. reporting obligations.
COSCIENS Biopharma (OTCQB: CSCIF, TSX: CSCI) detailed a share capital amendment effective July 3, 2026. The plan includes a 1-for-150 share consolidation followed by a 50-for-1 split, leaving ongoing shareholders with one-third of their pre-Consolidation holdings (subject to rounding).
Holders of fewer than 150 shares on the Effective Date will be cashed out at US$1.60 per pre-Consolidation share. COSCIENS also plans to file Form 15 with the SEC to suspend U.S. reporting obligations.
COSCIENS Biopharma (TSX: CSCI, OTCQB: CSCIF) reported results of its June 18, 2026 shareholder meeting. Shareholders approved all items, including director re-election, auditor re-appointment and a share capital amendment involving a 1-for-150 consolidation followed by a 50-for-1 share split.
The board also appointed Peter H. Puccetti, previously interim CEO and board chair, as permanent full-time President and CEO, effective immediately, with a mandate to strengthen operational performance and align resources with key strategic priorities.
COSCIENS Biopharma (OTCQB: CSCIF) reported Q1 2026 net income of $10.8 million, or $3.42 per share, versus a $3.7 million loss in Q1 2025, driven mainly by $10.9 million income from discontinued German operations.
Revenue rose to $1.9 million and operating expenses fell to $1.5 million, reducing the net loss from continuing operations to $0.2 million. The company deconsolidated its insolvent German subsidiaries, plans a share reorganization to suspend SEC reporting, and decided not to advance the AvenActive program.
COSCIENS Biopharma (OTCQB: CSCIF) filed a Rule 13e-3 Transaction Statement with the SEC on April 20, 2026 proposing a two-step Share Capital Amendment to reduce U.S. holders of record below 300 and seek suspension of Exchange Act reporting.
The plan consolidates 150 pre-consolidation shares into one, then splits 50-for-1; holders under 150 would receive US$1.60 per pre-consolidation share and be cashed out. The company estimates approximately US$1.9 million in annualized cost savings if SEC Reporting Suspension is allowed. Shareholder approval at the June 2026 meeting is planned.
COSCIENS Biopharma (OTCQB: CSCIF; TSX: CSCI) issued a notice on April 7, 2026 responding to recent unusual market activity. The company said it does not normally comment on market speculation and confirmed it is not aware of any material undisclosed information that would explain the recent trading increase.
COSCIENS Biopharma (OTCQB: CSCIF, TSX: CSCI) reported Q4 and full‑year 2025 results and a corporate update on March 25, 2026. The company ended 2025 with $7.3M cash, Q4 net loss of $2.2M and FY net loss of $10.4M. Revenue for FY 2025 was $7.5M. Management ceased funding its German subsidiaries and filed for insolvency there on March 23, 2026, expecting ~$1.9M annualized cost savings and removal of €11.0M pension liabilities from consolidation. The company plans to propose suspending Exchange Act reporting while remaining a Canadian reporting issuer and listed on the TSX and OTC market.